Congrès AFSOS

Les 12/13 Octobre se tiendra à Paris, le 9e congrès national des soins oncologiques de support organisé par l’AFSOS. Le laboratoire Natsuca ( http://laboratoire-natsuca.com/natsuca/) y présentera les résultats d’une étude réalisée en collaboration avec les équipes de 4P-Pharma.

Le ginseng est utilisé par les patients atteints de cancer, et notamment de cancer du sein, afin d’améliorer les symptômes de grande fatigue ressentis durant, ou suite à, un traitement chimiothérapeutique.   L’étude réalisée ici a permis de montrer que le “Qiseng® n’affecte pas l’inhibition de la croissance tumorale induite par la doxorubicine sur un modèle de xénogreffe de cancer du sein hormono-sensible , mesurée sur le volume tumoral in vivo ou le poids ex vivo de la tumeur.”

“Evaluation de la sécurité d’emploi de Qiseng®, produit à base de ginseng américain (Panax quinquefolius), dans un modèle murin de xénogreffe de cancer du sein hormono-sensible “

C. Feger 1, O. Magnard 1, C. Martin 2, I. Lamensdorf 2, D. Kaeuffer 1, F. Petitjean 1

1: Natsuca, Castres, France 2: 4P-Pharma, Lille, France

 

9e-congrès-AFSOS-site

 

4P-Pharma at BPI Innogeneration

Our BD team will attend the next BPI Innogeneration on thursday october 12th.

If you would like to discuss about potential collaboration and  early-stage technologies in the field of oncology and inflammation, do not hesitate to contact us: contact at 4p-pharma.com

See you there!

 

 

Bpifrance-Inno-Generation-3_image_628x313

4P-Pharma an actor in ADHD pipeline drug development

4P-Pharma is a recognized actor in the ADHD pipeline drug development.

Stimulant abuse and addiction is a major global health problem and prescription drugs are indeed more and more abused, in virtue of their “rewarding” psychotropic effects.  ADHD medications abuse increased by 4 fold, and led to a 400% increased in emergency room visits from 2006 to 2014.  4P-003 is our innovative product developed as a novel deterrent approach for stimulant misuse, under a 505(b)2 approval.

https://www.businesswire.com/news/home/20170821005375/en/Attention-Deficit-Hyperactivity-Disorder-ADHD—Pipeline

 

 

Conference talk at the Luxembourg Institute of Health

At the invitation of the Luxembourg Institute of Health, Revital Rattenbach, CEO of 4P-Pharma, will be giving a presentation at the Institute on July 12th. This talk is part of the lecture series biomedical research organized by the LIH.

 

Lecture Series Biomedical Research: from discovery to patients : Key Factors in Preclinical and Early Clinical Development

 

Schedule:

11.00 – 12.30   Lecture
12.30 – 13.30   Workshop
House of Biohealth Conference Room

Luxembourg Institute of Health
29, rue Henri Koch
Esch-sur-Alzette L-4354
Luxembourg

lih-logo

4P-Pharma at Pierre Fabre DayONE innovation day

4P-Pharma was selected to give a pitch at the Pierre Fabre DayONE open innovation day on June 14th in Toulouse.

The one day conference aim is to  identify, and develop innovative projects from biopharmaceutical companies, start-ups, and research laboratories (public or private) specialized in oncology, dermatology or consumer healthcare.

rtaImage

4P-Pharma at Meet2Win 2017

4P Pharma’s CEO, Revital Rattenbach, and our business developer Luigi Formicola, will be attending the upcoming MEET2WIN Oncology Business convention in Bordeaux, May 11-12th 2017.

4P-Pharma develops innovative drugs notably in the oncology field. We partner with academic institutions, TTOs, and biotech/pharma companies, our adaptative collaborative on a co-share co-risk model.

Contact us via the partnering platform to schedule a meeting and discuss collaboration opportunities.

 

 

2017_meet2win_logo